Bacteria-mediated immunotheraphy
Employees: 11-50
Total raised: $5M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Muirwoods ... | muirwoodsv... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.07.2019 | Seed | $5M | - |
Mentions in press and media 6
| Date | Title | Description | Source |
| 29.03.2024 | LISCure Biosciences receives U.S. FDA Fast Track designation... | Phase 2 study is underway and LB-P8 is the only live biotherapeutic product currently reported to be... | en.prnasia... |
| 08.12.2022 | LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designa... | First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic disease... | en.prnasia... |
| 28.10.2022 | LISCure Biosciences Announces Oral Presentation of New Drug ... | The efficacy and mechanism of NASH microbiome-based therapy for liver fibrosis, steatosis, and infla... | en.prnasia... |
| 27.02.2021 | LISCure Biosciences Raises $21 million in Series B Funding | South Korea: On February 25th, 2021, LISCure Biosciences Inc., a biotech company that focuses on dev... | incubees.c... |
| 26.02.2021 | South Korea-based biotech startup LISCure Biosciences secure... | The use of immunotherapy treatments for cancer has been gaining momentum in recent years as governme... | techstartu... |
| 25.07.2019 | Liscure Biosciences Raises $5M in Seed Funding | LISCure Biosciences, a Seoul, South Korea-based biotech company that researches and develops bacteri... | finsmes.co... |